Evidence map›Paper›PMID 37889361›Full record

ReviewEJNMMI radiopharmacy and chemistry2023

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Jean DaSilva, Clemens Decristoforo, Robert H Mach, Guy Bormans, Giuseppe Carlucci, Mohammed Al-Qahtani, Adriano Duatti, Antony D Gee, Wiktor Szymanski, Sietske Rubow and 12 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EJNMMI radiopharmacy and chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Functionalization ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jean DaSilvaUniversity of Montreal, Montreal, Canada.
Clemens DecristoforoMedical University Innsbruck, Innsbruck, Austria.
Robert H MachUniversity of Pennsylvania, Philadelphia, USA.
Guy BormansUniversity of Leuven, Leuven, Belgium.
Giuseppe CarlucciUCLA, Los Angeles, USA.
Mohammed Al-QahtaniKing Faisal Specialist Hospital and Research Center, Riad, Saudi Arabia.
Adriano DuattiUniversity of Ferrara, Ferrara, Italy.
Antony D GeeKing's College, London, UK.
Wiktor SzymanskiUniversity of Groningen, Groningen, The Netherlands.
Sietske RubowStellenbosch University, Stellenbosch, South Africa.
Jeroen HendrikxNKI, Amsterdam, The Netherlands.
Xing YangPeking University First Hospital, Beijing, China.
Hongmei JiaBeijing Normal University, Beijing, China.
Junbo ZhangBeijing Normal University, Beijing, China.
Peter CaravanMassuchusetts General Hospital, Harvard University, Boston, USA.
Hua YangTRIUMF, Vancouver, Canada.
Jan Rijn ZeevaartNecsa, Pretoria, South Africa.
Miguel Avila RodriquezUniversidad Nacional Autonoma de Mexico (UNAM), Mexico-City, Mexico.
Ralph Santos OliveiraBrazilian Association of Radiopharmacy Brazil, Brazilian Nuclear Energy Commission - Nuclear Engineering Institute, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
Marcela ZubillagaUniversity of Buenos Aires, Buenos Aires, Argentina.
Tamer SakrEgyptian Atomic Energy Authority, Cairo, Egypt.
Sarah SpreckelmeyerDepartment of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353, Berlin, Germany. sarah.spreckelmeyer@charite.de.ORCID http://orcid.org/0000-0003-1348-0309

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. MAIN BODY: This selection of highlights provides commentary on 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals.

conclusionTrends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field in many aspects.

Indexed as

Highlight articlesNuclear medicineRadiochemistryRadiopharmaceutical sciencesRadiopharmacyTrends in radiopharmaceutical sciences

Identifiers

PMID37889361
PMCPMC10611660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.